In a head-to-head Phase 3 trial, prifemilast nearly doubled the rate of PASI 75 response compared with apremilast and achieved superiority on both co-primary endpoints Results support the potential of prifemilast to deliver greater efficacy than apremilast, with low rates of serious...
Hence then, the article about prifemilast demonstrates superior efficacy vs apremilast in newsoara s head to head phase 3 psoriasis trial campfield advancing the potential best in class oral pde4 inhibitor in ibd was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Prifemilast Demonstrates Superior Efficacy vs. Apremilast in Newsoara's Head-to-Head Phase 3 Psoriasis Trial; cAMPfield Advancing the Potential Best-in-Class Oral PDE4 Inhibitor in IBD )
Also on site :
- In 1924, Caesar Cardini ran out of kitchen supplies in a Fourth of July rush at his Tijuana restaurant; he tossed romaine with what was left, and the salad carries his name
- Viola Davis, 61, Opens Up About ‘Extremely Painful’ Health Condition for the First Time: ‘It Terrified Me’ (Exclusive)
- Rosalía Shuts Down Kenan Thompson’s Idea for a Pop-Classical Album in Hilarious ‘SNL’ Promo: ‘That’s LUX’